FOLH1 and prostate carcinoma: Given the increasing use of targeted radionuclide therapies, such as PRLT in prostate cancer, where 177Lu-PSMA and 225Ac-PSMA represent the most commonly employed radiopharmaceuticals, it is imperative to evaluate whether the usage of PARPi can improve the efficacy of this therapeutic modality.